Equities research analysts predict that Cellectis SA (NASDAQ:CLLS) will announce sales of $1.93 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Cellectis’ earnings. The lowest sales estimate is $500,000.00 and the highest is $3.00 million. Cellectis posted sales of $2.19 million during the same quarter last year, which suggests a negative year-over-year growth rate of 11.9%. The company is scheduled to report its next quarterly earnings report on Tuesday, November 12th.
On average, analysts expect that Cellectis will report full-year sales of $12.24 million for the current fiscal year, with estimates ranging from $10.14 million to $14.00 million. For the next financial year, analysts forecast that the business will post sales of $48.30 million, with estimates ranging from $15.00 million to $82.00 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Cellectis.
Cellectis (NASDAQ:CLLS) last released its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.18). The company had revenue of $2.93 million during the quarter, compared to the consensus estimate of $3.45 million. Cellectis had a negative return on equity of 21.51% and a negative net margin of 813.06%.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CLLS. ARK Investment Management LLC boosted its holdings in shares of Cellectis by 18.1% in the 2nd quarter. ARK Investment Management LLC now owns 1,103,186 shares of the biotechnology company’s stock valued at $17,210,000 after buying an additional 169,110 shares during the period. Nikko Asset Management Americas Inc. boosted its holdings in shares of Cellectis by 48.9% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,224,334 shares of the biotechnology company’s stock valued at $19,100,000 after buying an additional 401,888 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Cellectis by 48.1% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,210,019 shares of the biotechnology company’s stock valued at $18,876,000 after buying an additional 392,841 shares during the period. Aperio Group LLC acquired a new position in shares of Cellectis in the 2nd quarter valued at about $147,000. Finally, Deutsche Bank AG boosted its holdings in shares of Cellectis by 178.8% in the 4th quarter. Deutsche Bank AG now owns 47,700 shares of the biotechnology company’s stock valued at $794,000 after buying an additional 30,589 shares during the period. 32.30% of the stock is owned by institutional investors.
Shares of CLLS traded up $0.07 during midday trading on Tuesday, hitting $12.67. The company had a trading volume of 44,426 shares, compared to its average volume of 105,769. The company’s 50 day moving average price is $13.02 and its 200 day moving average price is $16.51. The stock has a market cap of $534.87 million, a price-to-earnings ratio of -6.56 and a beta of 1.76. Cellectis has a 52 week low of $11.53 and a 52 week high of $29.40. The company has a quick ratio of 8.46, a current ratio of 8.47 and a debt-to-equity ratio of 0.11.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Featured Article: How a Strangle Strategy is different from a Straddle Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.